Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| MYRIAD GENETICS INCMYGN · Entity 5953 | Chief Operating Officer | April 14, 2026 | April 15, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
MYRIAD GENETICS INC
Report date April 14, 2026 · Filed April 15, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 629,646 |
Reported balance
After 2026-04-14 transaction · row 1
1 source rowRow 1 · 2026-04-14 · Tax withholding · Disposed 1,069 · Balance 629,646 F1: Represents shares of Common Stock withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock units previously granted to the Reporting Person. The number of shares withheld was determined based on the closing price of Issuer's Common Stock on April 14, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares of Common Stock withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock units previously granted to the Reporting Person. The number of shares withheld was determined based on the closing price of Issuer's Common Stock on April 14, 2026.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 14, 2026 Filed Apr 15, 2026 20:20 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Tax withholdingCommon Stock | 1,069 | $4.91 | $5,248.79 |
DisclosureSEC source: 0001517026-26-000008 · wk-form4_1776284439.xml · nonDerivative · entry 1 Verratti Mark · CIK 0001517026 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 629,646 F1 · shares: Represents shares of Common Stock withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock units previously granted to the Reporting Person. The number of shares withheld was determined based on the closing price of Issuer's Common Stock on April 14, 2026. Read SEC document |
| March 22, 2026 Filed Mar 23, 2026 20:22 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Tax withholdingCommon Stock | 2,055 | $4.58 | $9,411.90 |
DisclosureSEC source: 0001517026-26-000006 · wk-form4_1774297376.xml · nonDerivative · entry 1 Verratti Mark · CIK 0001517026 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 630,715 F1 · shares: Represents shares of Common Stock withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock units previously granted to the Reporting Person. The number of shares withheld was determined based on the closing price of Issuer's Common Stock on March 20, 2026. Read SEC document |
| March 15, 2026 Filed Mar 16, 2026 21:05 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Tax withholdingCommon Stock | 9,096 | $4.66 | $42,387.36 |
DisclosureSEC source: 0001517026-26-000004 · wk-form4_1773695137.xml · nonDerivative · entry 5 Verratti Mark · CIK 0001517026 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 632,770 F3 · shares: Represents shares of Common Stock withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of performance-based restricted stock units previously granted to the Reporting Person. The number of shares withheld was determined based on the closing price of the Issuer's Common Stock on March 13, 2026. Read SEC document |
| March 15, 2026 Filed Mar 16, 2026 21:05 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Tax withholdingCommon Stock | 5,611 | $4.66 | $26,147.26 |
DisclosureSEC source: 0001517026-26-000004 · wk-form4_1773695137.xml · nonDerivative · entry 4 Verratti Mark · CIK 0001517026 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 641,866 F2 · shares: Represents shares of Common Stock withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock units previously granted to the Reporting Person. The number of shares withheld was determined based on the closing price of Issuer's Common Stock on March 13, 2026. Read SEC document |
| March 14, 2026 Filed Mar 16, 2026 21:05 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Tax withholdingCommon Stock | 5,418 | $4.66 | $25,247.88 |
DisclosureSEC source: 0001517026-26-000004 · wk-form4_1773695137.xml · nonDerivative · entry 3 Verratti Mark · CIK 0001517026 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 647,477 F2 · shares: Represents shares of Common Stock withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock units previously granted to the Reporting Person. The number of shares withheld was determined based on the closing price of Issuer's Common Stock on March 13, 2026. Read SEC document |
| March 13, 2026 Filed Mar 16, 2026 21:05 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Tax withholdingCommon Stock | 9,164 | $4.66 | $42,704.24 |
DisclosureSEC source: 0001517026-26-000004 · wk-form4_1773695137.xml · nonDerivative · entry 2 Verratti Mark · CIK 0001517026 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 652,895 F2 · shares: Represents shares of Common Stock withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock units previously granted to the Reporting Person. The number of shares withheld was determined based on the closing price of Issuer's Common Stock on March 13, 2026. Read SEC document |
| March 12, 2026 Filed Mar 16, 2026 21:05 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | GrantCommon Stock | 247,423 | $0.00 | $0.00 |
DisclosureSEC source: 0001517026-26-000004 · wk-form4_1773695137.xml · nonDerivative · entry 1 Verratti Mark · CIK 0001517026 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 662,059 F1 · shares: Consists of time-based restricted stock units granted pursuant to the Issuer's 2017 Employee, Director and Consultant Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock and vests in three equal annual installments beginning on the first anniversary of the grant date. Read SEC document |
| February 02, 2026 Filed Feb 3, 2026 22:30 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | GrantCommon Stock | 32,810 | $0.00 | $0.00 |
DisclosureSEC source: 0001517026-26-000002 · wk-form4_1770157806.xml · nonDerivative · entry 1 Verratti Mark · CIK 0001517026 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 414,636 F1 · shares: Consists of performance-based restricted stock units (PSUs) initially granted on March 15, 2023, subject to accomplishment of pre-determined performance metrics. On February 2, 2026, the Compensation and Human Capital Committee of the Company's Board of Directors determined the final award amount based on the accomplishment of the applicable performance metrics. Each PSU represents a contingent right to receive one share of the Company's common stock and vests on March 15, 2026. Read SEC document |
| September 21, 2025 Filed Sep 22, 2025 20:16 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Tax withholdingCommon Stock | 1,085 | $7.77 | $8,430.45 |
DisclosureSEC source: 0001517026-25-000008 · wk-form4_1758572179.xml · nonDerivative · entry 1 Verratti Mark · CIK 0001517026 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 381,826 F1 · shares: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the reporting person. The number of shares of Myriad common stock withheld was determined based on the closing price of Myriad common stock on September 19, 2025. Read SEC document |
| April 30, 2025 Filed May 1, 2025 20:27 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | GrantPerformance-Based Restricted Stock Units · Derivative | 105,785 | $0.00 | $0.00 |
DisclosureSEC source: 0001517026-25-000005 · wk-form4_1746131228.xml · derivative · entry 1 Verratti Mark · CIK 0001517026 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 105,785 Underlying: Common Stock · 105,785 shares Expires not disclosed F1 · derivative.exercise_price: The shares subject to the performance-based restricted stock units ("PSUs") represent the maximum number of shares that may vest based on the Issuer's achievement of specified stock price milestones. The PSUs will vest upon certification by the Compensation and Human Capital Committee as to 25% of the shares upon the achievement of each of four stock price milestones, subject to the reporting person's continued employment or service through the applicable vesting date; provided; however, that no portion of the PSUs may vest earlier than April 30, 2026. F1 · derivative.exercise_date: The shares subject to the performance-based restricted stock units ("PSUs") represent the maximum number of shares that may vest based on the Issuer's achievement of specified stock price milestones. The PSUs will vest upon certification by the Compensation and Human Capital Committee as to 25% of the shares upon the achievement of each of four stock price milestones, subject to the reporting person's continued employment or service through the applicable vesting date; provided; however, that no portion of the PSUs may vest earlier than April 30, 2026. F1 · derivative.expiration_date: The shares subject to the performance-based restricted stock units ("PSUs") represent the maximum number of shares that may vest based on the Issuer's achievement of specified stock price milestones. The PSUs will vest upon certification by the Compensation and Human Capital Committee as to 25% of the shares upon the achievement of each of four stock price milestones, subject to the reporting person's continued employment or service through the applicable vesting date; provided; however, that no portion of the PSUs may vest earlier than April 30, 2026. Read SEC document |
| April 14, 2025 Filed Apr 15, 2025 20:12 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Tax withholdingCommon Stock | 1,085 | $8.08 | $8,766.80 |
DisclosureSEC source: 0001517026-25-000002 · wk-form4_1744747947.xml · nonDerivative · entry 1 Verratti Mark · CIK 0001517026 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 382,911 F1 · shares: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the reporting person. The number of shares of Myriad common stock withheld was determined based on the closing price of Myriad common stock on April 14, 2025. Read SEC document |
| March 24, 2025 Filed Mar 25, 2025 20:16 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Tax withholdingCommon Stock | 1,605 | $9.98 | $16,017.90 |
DisclosureSEC source: 0001628280-25-014724 · wk-form4_1742933792.xml · nonDerivative · entry 4 Verratti Mark · CIK 0001517026 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 383,996 F4 · shares: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of performance-based restricted stock units granted to the reporting person. The number of shares of Myriad common stock withheld was determined based on the closing price of Myriad common stock on March 24, 2025. Read SEC document |
| March 24, 2025 Filed Mar 25, 2025 20:16 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Tax withholdingCommon Stock | 1,096 | $9.98 | $10,938.08 |
DisclosureSEC source: 0001628280-25-014724 · wk-form4_1742933792.xml · nonDerivative · entry 3 Verratti Mark · CIK 0001517026 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 385,601 F3 · shares: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the reporting person. The number of shares of Myriad common stock withheld was determined based on the closing price of Myriad common stock on March 24, 2025. Read SEC document |
| March 22, 2025 Filed Mar 25, 2025 20:16 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Tax withholdingCommon Stock | 3,623 | $10.01 | $36,266.23 |
DisclosureSEC source: 0001628280-25-014724 · wk-form4_1742933792.xml · nonDerivative · entry 2 Verratti Mark · CIK 0001517026 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 386,697 F2 · shares: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of performance-based restricted stock units granted to the reporting person. The number of shares of Myriad common stock withheld was determined based on the closing price of Myriad common stock on March 21, 2025. Read SEC document |
| March 22, 2025 Filed Mar 25, 2025 20:16 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Tax withholdingCommon Stock | 1,366 | $10.01 | $13,673.66 |
DisclosureSEC source: 0001628280-25-014724 · wk-form4_1742933792.xml · nonDerivative · entry 1 Verratti Mark · CIK 0001517026 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 390,320 F1 · shares: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the reporting person. The number of shares of Myriad common stock withheld was determined based on the closing price of Myriad common stock on March 21, 2025. Read SEC document |
| March 15, 2025 Filed Mar 17, 2025 20:19 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Tax withholdingCommon Stock | 3,729 | $10.07 | $37,551.03 |
DisclosureSEC source: 0001628280-25-013145 · wk-form4_1742242769.xml · nonDerivative · entry 3 Verratti Mark · CIK 0001517026 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 391,686 F2 · shares: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the reporting person. The number of shares of Myriad common stock withheld was determined based on the closing price of Myriad common stock on March 14, 2025. Read SEC document |
| March 14, 2025 Filed Mar 17, 2025 20:19 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Tax withholdingCommon Stock | 5,847 | $10.07 | $58,879.29 |
DisclosureSEC source: 0001628280-25-013145 · wk-form4_1742242769.xml · nonDerivative · entry 2 Verratti Mark · CIK 0001517026 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 395,415 F2 · shares: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the reporting person. The number of shares of Myriad common stock withheld was determined based on the closing price of Myriad common stock on March 14, 2025. Read SEC document |
| March 13, 2025 Filed Mar 17, 2025 20:19 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | GrantCommon Stock | 99,227 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-25-013145 · wk-form4_1742242769.xml · nonDerivative · entry 1 Verratti Mark · CIK 0001517026 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 401,262 F1 · shares: Consists of time-based restricted stock units granted pursuant to the Company's 2017 Employee, Director and Consultant Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of the Company's common stock and vests in three equal annual installments beginning on the first anniversary of the grant date. Read SEC document |
| February 07, 2025 Filed Mar 5, 2025 00:31 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | GrantCommon Stock | 12,758 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-25-010136 · wk-form4_1741134675.xml · nonDerivative · entry 1 Verratti Mark · CIK 0001517026 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 302,035 F1 · shares: Consists of performance-based restricted stock units (PSUs) initially granted on March 22, 2022, subject to accomplishment of pre-determined performance metrics. On February 7, 2025, the Compensation and Human Capital Committee of the Company's Board of Directors determined the final award amount based on the accomplishment of the applicable performance metrics. Each PSU represents a contingent right to receive one share of the Company's common stock and vests on March 22, 2025. Read SEC document |
| October 09, 2024 Filed Oct 10, 2024 20:36 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Tax withholdingCommon Stock | 5,004 | $24.37 | $121,947.48 |
DisclosureSEC source: 0001517026-24-000006 · wk-form4_1728592566.xml · nonDerivative · entry 2 Verratti Mark · CIK 0001517026 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 289,277 F2 · shares: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of performance-based restricted stock units granted to the reporting person. The number of shares of Myriad common stock withheld was determined based on the closing price of Myriad common stock on October 9, 2024. Read SEC document |
| October 09, 2024 Filed Oct 10, 2024 20:36 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Tax withholdingCommon Stock | 3,359 | $24.37 | $81,858.83 |
DisclosureSEC source: 0001517026-24-000006 · wk-form4_1728592566.xml · nonDerivative · entry 1 Verratti Mark · CIK 0001517026 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 294,281 F1 · shares: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the reporting person. The number of shares of Myriad common stock withheld was determined based on the closing price of Myriad common stock on October 9, 2024. Read SEC document |
| September 21, 2024 Filed Sep 23, 2024 20:21 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Tax withholdingCommon Stock | 1,075 | $27.64 | $29,713.00 |
DisclosureSEC source: 0001517026-24-000004 · wk-form4_1727122860.xml · nonDerivative · entry 1 Verratti Mark · CIK 0001517026 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 297,640 F1 · kind: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the reporting person. The number of shares of Myriad common stock withheld was determined based on the closing price of Myriad common stock on September 20, 2024. Read SEC document |
| April 14, 2024 Filed Apr 15, 2024 20:25 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Tax withholdingCommon Stock | 1,076 | $19.55 | $21,035.80 |
DisclosureSEC source: 0001517026-24-000002 · wk-form4_1713212713.xml · nonDerivative · entry 1 Verratti Mark · CIK 0001517026 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 298,715 F1 · kind: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the reporting person. The number of shares of Myriad common stock withheld was determined based on the closing price of Myriad common stock on April 12, 2024. Read SEC document |
| March 24, 2024 Filed Mar 25, 2024 20:31 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Tax withholdingCommon Stock | 1,584 | $22.24 | $35,228.16 |
DisclosureSEC source: 0001628280-24-012915 · wk-form4_1711398651.xml · nonDerivative · entry 3 Verratti Mark · CIK 0001517026 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 299,791 F2 · kind: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of performance-based restricted stock units granted to the reporting person. The number of shares of Myriad common stock withheld was determined based on the closing price of Myriad common stock on March 22, 2024. Read SEC document |
| March 24, 2024 Filed Mar 25, 2024 20:31 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Tax withholdingCommon Stock | 1,661 | $22.24 | $36,940.64 |
DisclosureSEC source: 0001628280-24-012915 · wk-form4_1711398651.xml · nonDerivative · entry 2 Verratti Mark · CIK 0001517026 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 301,375 F1 · kind: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the reporting person. The number of shares of Myriad common stock withheld was determined based on the closing price of Myriad common stock on March 22, 2024. Read SEC document |
| March 22, 2024 Filed Mar 25, 2024 20:31 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Tax withholdingCommon Stock | 1,648 | $22.24 | $36,651.52 |
DisclosureSEC source: 0001628280-24-012915 · wk-form4_1711398651.xml · nonDerivative · entry 1 Verratti Mark · CIK 0001517026 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 303,036 F1 · kind: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the reporting person. The number of shares of Myriad common stock withheld was determined based on the closing price of Myriad common stock on March 22, 2024. Read SEC document |
| March 15, 2024 Filed Mar 18, 2024 20:45 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Tax withholdingCommon Stock | 3,686 | $21.16 | $77,995.76 |
DisclosureSEC source: 0001628280-24-011681 · wk-form4_1710794695.xml · nonDerivative · entry 2 Verratti Mark · CIK 0001517026 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 304,684 F2 · kind: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the reporting person. The number of shares of Myriad common stock withheld was determined based on the closing price of Myriad common stock on March 15, 2024. Read SEC document |
| March 14, 2024 Filed Mar 18, 2024 20:45 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | GrantCommon Stock | 58,631 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-24-011681 · wk-form4_1710794695.xml · nonDerivative · entry 1 Verratti Mark · CIK 0001517026 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 308,370 F1 · kind: Consists of time-based restricted stock units granted pursuant to the Company's 2017 Employee, Director and Consultant Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of the Company's common stock and vests in three equal annual installments beginning on the first anniversary of the grant date. Read SEC document |
| October 09, 2023 Filed Oct 10, 2023 20:21 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Tax withholdingCommon Stock | 5,006 | $15.01 | $75,140.06 |
DisclosureSEC source: 0001517026-23-000009 · wk-form4_1696969253.xml · nonDerivative · entry 2 Verratti Mark · CIK 0001517026 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 249,739 F2 · kind: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of performance-based restricted stock units granted to the reporting person. The number of shares of Myriad common stock withheld was determined based on the closing price of Myriad common stock on October 9, 2023. Read SEC document |
| October 09, 2023 Filed Oct 10, 2023 20:21 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Tax withholdingCommon Stock | 3,360 | $15.01 | $50,433.60 |
DisclosureSEC source: 0001517026-23-000009 · wk-form4_1696969253.xml · nonDerivative · entry 1 Verratti Mark · CIK 0001517026 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 254,745 F1 · kind: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the reporting person. The number of shares of Myriad common stock withheld was determined based on the closing price of Myriad common stock on October 9, 2023. Read SEC document |
| September 26, 2023 Filed Sep 27, 2023 20:30 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Tax withholdingCommon Stock | 3,523 | $15.99 | $56,332.77 |
DisclosureSEC source: 0001517026-23-000007 · wk-form4_1695846619.xml · nonDerivative · entry 1 Verratti Mark · CIK 0001517026 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 258,105 F1 · kind: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of performance-based restricted stock units granted to the reporting person. The number of shares of Myriad common stock withheld was determined based on the closing price of Myriad common stock on September 26, 2023. Read SEC document |
| September 21, 2023 Filed Sep 22, 2023 20:26 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Tax withholdingCommon Stock | 1,076 | $16.77 | $18,044.52 |
DisclosureSEC source: 0001517026-23-000005 · wk-form4_1695414390.xml · nonDerivative · entry 1 Verratti Mark · CIK 0001517026 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 261,628 F1 · kind: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the reporting person. The number of shares of Myriad common stock withheld was determined based on the closing price of Myriad common stock on September 21, 2023. Read SEC document |
| April 14, 2023 Filed Apr 17, 2023 22:22 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Tax withholdingCommon Stock | 703 | $22.27 | $15,655.81 |
DisclosureSEC source: 0001517026-23-000002 · wf-form4_168177016388393.xml · nonDerivative · entry 1 Verratti Mark · CIK 0001517026 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 262,704 F1 · kind: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the reporting person. The number of shares of Myriad common stock withheld was determined based on the closing price of Myriad common stock on April 14, 2023. Read SEC document |
| March 24, 2023 Filed Mar 27, 2023 20:27 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Tax withholdingCommon Stock | 1,586 | $23.72 | $37,619.92 |
DisclosureSEC source: 0001628280-23-009262 · wf-form4_167994886476875.xml · nonDerivative · entry 2 Verratti Mark · CIK 0001517026 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 263,407 F2 · kind: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of performance-based restricted stock units granted to the reporting person. The number of shares of Myriad common stock withheld was determined based on the closing price of Myriad common stock on March 24, 2023. Read SEC document |
| March 24, 2023 Filed Mar 27, 2023 20:27 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Tax withholdingCommon Stock | 1,083 | $23.72 | $25,688.76 |
DisclosureSEC source: 0001628280-23-009262 · wf-form4_167994886476875.xml · nonDerivative · entry 1 Verratti Mark · CIK 0001517026 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 264,993 F1 · kind: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the reporting person. The number of shares of Myriad common stock withheld was determined based on the closing price of Myriad common stock on March 24, 2023. Read SEC document |
| March 22, 2023 Filed Mar 23, 2023 20:28 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Tax withholdingCommon Stock | 1,351 | $22.91 | $30,951.41 |
DisclosureSEC source: 0001628280-23-009049 · wf-form4_167960329972877.xml · nonDerivative · entry 1 Verratti Mark · CIK 0001517026 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 266,076 F1 · kind: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the reporting person. The number of shares of Myriad common stock withheld was determined based on the closing price of Myriad common stock on March 22, 2023. Read SEC document |
| March 15, 2023 Filed Mar 16, 2023 20:29 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | GrantCommon Stock | 39,405 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-23-008316 · wf-form4_167899855540034.xml · nonDerivative · entry 1 Verratti Mark · CIK 0001517026 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 267,427 F1 · kind: Consists of time-based restricted stock units granted pursuant to the Company's 2017 Employee, Director and Consultant Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of the Company's common stock and vests in three equal annual installments beginning on the first anniversary of the grant date. Read SEC document |
| October 09, 2022 Filed Oct 11, 2022 20:35 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Tax withholdingCommon Stock | 5,006 | $19.62 | $98,217.72 |
DisclosureSEC source: 0001628280-22-026252 · wf-form4_166552048411646.xml · nonDerivative · entry 2 Verratti Mark · CIK 0001517026 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 228,022 F2 · kind: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of performance-based restricted stock units granted to the reporting person. The number of shares of Myriad common stock withheld was determined based on the closing price of Myriad common stock on October 7, 2022. Read SEC document |
| October 09, 2022 Filed Oct 11, 2022 20:35 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Tax withholdingCommon Stock | 3,360 | $19.62 | $65,923.20 |
DisclosureSEC source: 0001628280-22-026252 · wf-form4_166552048411646.xml · nonDerivative · entry 1 Verratti Mark · CIK 0001517026 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 233,028 F1 · kind: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the reporting person. The number of shares of Myriad common stock withheld was determined based on the closing price of Myriad common stock on October 7, 2022. Read SEC document |
| September 26, 2022 Filed Sep 27, 2022 20:32 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Tax withholdingCommon Stock | 2,293 | $18.41 | $42,214.13 |
DisclosureSEC source: 0001628280-22-025565 · wf-form4_166431070757532.xml · nonDerivative · entry 2 Verratti Mark · CIK 0001517026 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 236,388 F2 · kind: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of performance-based restricted stock units granted to the reporting person. The number of shares of Myriad common stock withheld was determined based on the closing price of Myriad common stock on September 26, 2022. Read SEC document |
| September 25, 2022 Filed Sep 27, 2022 20:32 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Tax withholdingCommon Stock | 2,793 | $18.69 | $52,201.17 |
DisclosureSEC source: 0001628280-22-025565 · wf-form4_166431070757532.xml · nonDerivative · entry 1 Verratti Mark · CIK 0001517026 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 238,681 F1 · kind: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the reporting person. The number of shares of Myriad common stock withheld was determined based on the closing price of Myriad common stock on September 23, 2022. Read SEC document |
| September 21, 2022 Filed Sep 22, 2022 20:38 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Tax withholdingCommon Stock | 702 | $20.20 | $14,180.40 |
DisclosureSEC source: 0001517026-22-000009 · wf-form4_166387912215433.xml · nonDerivative · entry 1 Verratti Mark · CIK 0001517026 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 241,474 F1 · kind: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the reporting person. The number of shares of Myriad common stock withheld was determined based on the closing price of Myriad common stock on September 21, 2022. Read SEC document |
| August 25, 2022 Filed Aug 26, 2022 20:23 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Tax withholdingCommon Stock | 1,031 | $24.89 | $25,661.59 |
DisclosureSEC source: 0001628280-22-023770 · wf-form4_166154538405411.xml · nonDerivative · entry 1 Verratti Mark · CIK 0001517026 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 242,176 F1 · kind: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the reporting person. The number of shares of Myriad common stock withheld was determined based on the closing price of Myriad common stock on August 25, 2022. Read SEC document |
| April 14, 2022 Filed Apr 14, 2022 21:00 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | GrantCommon Stock | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001517026-22-000008 · edgardoc.xml · nonDerivative · entry 1 Verratti Mark · CIK 0001517026 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 243,207 F1 · kind: Consists of time-based restricted stock units granted pursuant to the Company's 2017 Employee, Director and Consultant Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of the Company's common stock and vests in four equal annual installments beginning on the first anniversary of the grant date. Read SEC document |
| March 24, 2022 Filed Mar 25, 2022 21:06 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Tax withholdingCommon Stock | 1,584 | $25.32 | $40,106.88 |
DisclosureSEC source: 0001517026-22-000006 · edgardoc.xml · nonDerivative · entry 2 Verratti Mark · CIK 0001517026 · President, Mental Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 233,207 F2 · kind: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of performance-based restricted stock units granted to the reporting person. The number of shares of Myriad common stock withheld was determined based on the closing price of Myriad common stock on March 24, 2022. Read SEC document |
| March 24, 2022 Filed Mar 25, 2022 21:06 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Tax withholdingCommon Stock | 1,082 | $25.32 | $27,396.24 |
DisclosureSEC source: 0001517026-22-000006 · edgardoc.xml · nonDerivative · entry 1 Verratti Mark · CIK 0001517026 · President, Mental Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 234,791 F1 · kind: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the reporting person. The number of shares of Myriad common stock withheld was determined based on the closing price of Myriad common stock on March 24, 2022. Read SEC document |
| March 22, 2022 Filed Mar 23, 2022 20:52 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | GrantCommon Stock | 19,238 | $0.00 | $0.00 |
DisclosureSEC source: 0001517026-22-000004 · edgardoc.xml · nonDerivative · entry 1 Verratti Mark · CIK 0001517026 · President, Mental Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 235,873 F1 · kind: Consists of time-based restricted stock units granted pursuant to the Company's 2017 Employee, Director and Consultant Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of the Company's common stock and vests in four equal annual installments beginning on the first anniversary of the grant date. Read SEC document |
| February 16, 2022 Filed Feb 18, 2022 22:11 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | GrantCommon Stock | 22,616 | $0.00 | $0.00 |
DisclosureSEC source: 0001517026-22-000002 · edgardoc.xml · nonDerivative · entry 1 Verratti Mark · CIK 0001517026 · President, Mental Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 216,635 F1 · kind: Consists of performance-based restricted stock units (PSUs) granted pursuant to the Company's 2017 Employee, Director and Consultant Equity Incentive Plan. The PSUs were initially granted on March 24, 2021, subject to accomplishment of pre-determined performance metrics. On February 16, 2022, the Compensation and Human Capital Committee determined the final award amount based on the accomplishment of the applicable performance metrics. Each PSU represents a contingent right to receive one share of the Company's common stock, and vests 25% on March 24, 2022, 25% on March 24, 2023, 25% on March 24, 2024, and 25% on March 24, 2025. Read SEC document |
| October 09, 2021 Filed Oct 12, 2021 20:55 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Tax withholdingCommon Stock | 4,991 | $30.88 | $154,122.08 |
DisclosureSEC source: 0001517026-21-000009 · edgardoc.xml · nonDerivative · entry 2 Verratti Mark · CIK 0001517026 · President, Myriad Neuroscience 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 194,019 F2 · kind: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of performance-based restricted stock units granted to the reporting person. The number of shares of Myriad common stock withheld was determined based on the closing price of Myriad common stock October 8, 2021. Read SEC document |
| October 09, 2021 Filed Oct 12, 2021 20:55 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Tax withholdingCommon Stock | 3,349 | $30.88 | $103,417.12 |
DisclosureSEC source: 0001517026-21-000009 · edgardoc.xml · nonDerivative · entry 1 Verratti Mark · CIK 0001517026 · President, Myriad Neuroscience 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 199,010 F1 · kind: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the reporting person. The number of shares of Myriad common stock withheld was determined based on the closing price of Myriad common stock on October 8, 2021. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.